Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03357952
Title A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries ISR | ESP | BEL

Facility Status City State Zip Country Details
ZNA Stuivenberg Antwerpen 2060 Belgium Details
Algemeen Ziekenhuis Klina Brasschaat 2930 Belgium Details
AZ St.-Jan Brugge-Oostende AV Brugge 8000 Belgium Details
UZBrussel Brussel 1090 Belgium Details
UZA Edegem 2650 Belgium Details
UZ Gent Gent 9000 Belgium Details
Az Groeninge Kortrijk 8500 Belgium Details
Rambam Medical Center Haifa 31096 Israel Details
Carmel Hospital Haifa 34362 Israel Details
Hadassah Medical Center Jerusalem 91120 Israel Details
Sourasky Medical Center Tel-Aviv 6423906 Israel Details
Hosp. Univ. Germans Trias I Pujol Badalona 08916 Spain Details
Clinica Univ. de Navarra Pamplona 31008 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field